Suggested Remit: To appraise the clinical and cost effectiveness of voxelotor within its marketing authorisation for treating sickle cell disease .
Status Proposed
Process STA 2018
ID number 1403

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 June 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of voxelotor for treating sickle cell disease. We have recently invited stakeholders to respond to a written consultation on the draft scope. On receiving updated regulatory timing information from the company that is developing voxelotor, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on
23 May 2019 - 21 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance